MAPT and Alzheimer disease: Tideglusib has led to reduced amyloid deposition, lower levels of tau phosphorylation, prevention of hippocampal damage, fewer memory deficits and show anticonvulsant activity in rodents’ models of AD and epilepsy [124,126], (Figure 2, label 13).